Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Journal of Clinical Psychiatry|December 30, 2006
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorderMarc De Hert, Dita Kalnicka, Ruud van Winkel, et al.
The Journal of Clinical Psychiatry|August 7, 2008
Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening programRuud van Winkel, Jim van Os, Ivan Celic, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 23, 2011
Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label studyMartien Wampers, Linda Hanssens, Ruud van Winkel, et al.
Schizophrenia Research|October 22, 2008
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorderLinda Hanssens, Ruud van Winkel, Martien Wampers, et al.
Schizophrenia Research|February 27, 2008
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart reviewMarc De Hert, Vincent Schreurs, Kim Sweers, et al.
JAMA Cardiology|August 14, 2020
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical TrialPrakash Deedwania, Sabina A Murphy, Andre Scheen, et al.
Diabetes Care|January 10, 2018
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient PhenotypeEberhard Standl, Susanna R Stevens, Paul W Armstrong, et al.
The New England Journal of Medicine|March 16, 2010
Effect of valsartan on the incidence of diabetes and cardiovascular events, John J McMurray, Rury R Holman, et al.
The New England Journal of Medicine|March 16, 2010
Effect of nateglinide on the incidence of diabetes and cardiovascular events, Rury R Holman, Steven M Haffner, et al.
Pageof 2